Bicocca Open Archive

Logo unimib boa
CORTINOVIS, DIEGO LUIGI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.242
EU - Europa 2.671
AS - Asia 852
SA - Sud America 13
Continente sconosciuto - Info sul continente non disponibili 6
AF - Africa 5
OC - Oceania 4
Totale 8.793
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.168
IE - Irlanda 686
IT - Italia 594
DE - Germania 510
HK - Hong Kong 428
SE - Svezia 349
CN - Cina 302
UA - Ucraina 151
GB - Regno Unito 106
CA - Canada 73
AT - Austria 66
FI - Finlandia 65
IN - India 39
DK - Danimarca 38
FR - Francia 25
TR - Turchia 24
RU - Federazione Russa 23
BE - Belgio 20
JP - Giappone 19
NL - Olanda 19
VN - Vietnam 19
BR - Brasile 11
PL - Polonia 8
SG - Singapore 6
IR - Iran 5
EU - Europa 4
TW - Taiwan 3
AU - Australia 2
CL - Cile 2
JO - Giordania 2
MU - Mauritius 2
NZ - Nuova Zelanda 2
PT - Portogallo 2
SA - Arabia Saudita 2
SK - Slovacchia (Repubblica Slovacca) 2
A1 - Anonimo 1
A2 - ???statistics.table.value.countryCode.A2??? 1
BD - Bangladesh 1
BG - Bulgaria 1
CH - Svizzera 1
GN - Guinea 1
GR - Grecia 1
HU - Ungheria 1
IQ - Iraq 1
KR - Corea 1
MD - Moldavia 1
NG - Nigeria 1
PR - Porto Rico 1
RO - Romania 1
SC - Seychelles 1
SI - Slovenia 1
Totale 8.793
Salva come PNG Salva come JPEG
Città #
Ann Arbor 1.270
Dublin 665
Fairfield 533
Hong Kong 424
Woodbridge 411
Frankfurt am Main 367
Chandler 360
Ashburn 308
Wilmington 302
New York 265
Houston 231
Seattle 212
Cambridge 208
Jacksonville 168
Princeton 146
Milan 138
Dearborn 125
Lawrence 66
Vienna 64
Altamura 57
Shanghai 52
Nanjing 47
San Diego 44
Turin 41
London 36
Beijing 32
Helsinki 32
Guangzhou 30
Andover 25
Lachine 25
Toronto 23
Brussels 20
Rome 20
Ottawa 16
Boardman 15
Hebei 15
Tianjin 15
Assago 14
Dong Ket 14
Falls Church 13
Jinan 13
Los Angeles 12
Nanchang 12
Pune 12
Shenyang 11
Hangzhou 10
Norwalk 10
Bologna 9
Chicago 9
Lissone 9
Tokyo 9
Genoa 8
Lodi 8
Edmonton 7
Fremont 7
Monza 7
São Paulo 7
Bergamo 6
Bonndorf 6
Cesano Maderno 6
Changsha 6
Huizen 6
Lappeenranta 6
Ningbo 6
Redmond 6
Torre Del Greco 6
Zhengzhou 6
Carignano 5
Hefei 5
Lodz 5
Segrate 5
Torino 5
Alessandria 4
Carate Brianza 4
Groningen 4
Jiaxing 4
Kunming 4
Mountain View 4
New Bedfont 4
Perugia 4
Verona 4
Alcamo 3
Amsterdam 3
Baltimore 3
Broni 3
Camogli 3
Chiyoda-ku 3
Comazzo 3
Edinburgh 3
Gavirate 3
Gorgonzola 3
Kilburn 3
Lanzhou 3
Moscow 3
Paris 3
Phoenix 3
Prescot 3
Singapore 3
Trenton 3
Xian 3
Totale 7.187
Salva come PNG Salva come JPEG
Nome #
p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma 298
A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib 237
Evaluation of the psychometric properties of the EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20) 235
Validation of the Italian version of the full and abbreviated Trust in Oncologist Scale 222
Risk stratification of oxaliplatin induced peripheral neurotoxicity applying electrophysiological testing of dorsal sural nerve 213
Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS) 213
Genetic determinants of chronic oxaliplatin-induced peripheral neurotoxicity: A genome-wide study replication and meta-analysis 200
The Reproducibility of the Immunohistochemical PD-L1 Testing in Non-Small-Cell Lung Cancer: A Multicentric Italian Experience 197
Indicators of guideline-concordant care in lung cancer defined with a modified Delphi method and piloted in a cohort of over 5,800 cases 188
Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients 168
Neuropathic pain and chemotherapy-induced peripheral neurotoxicity: the issue 168
C-arm cone-beam CT-guided transthoracic lung core needle biopsy as a standard diagnostic tool 163
Correspondence between neurophysiological and clinical measurements of chemotherapy-induced peripheral neuropathy: secondary analysis of data from the CI-PeriNoms study 162
Incidence of atypical acute nerve hyperexcitability symptoms in oxaliplatin-treated patients with colorectal cancer 159
Chemotherapy-Induced Peripheral Neurotoxicity assessment: a critical revision of the currently available tools 159
Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin 157
Rasch-Transformed Total Neuropathy Score clinical version (RT-TNSc©) in patients with chemotherapy-induced peripheral neuropathy 153
Advanced age and liability to oxaliplatin-induced peripheral neuropathy: post hoc analysis of a prospective study 150
A Longitudinal Study on Oxaliplatin Induced Peripheral Neuropathy – Incidence and Facts About the “Real Life” Population And Actual Dose 149
Lack of Bax expression is associated with irinotecan-based treatment activity in advanced colorectal cancer patients 149
Neuroprotectant agents against oxaliplatin induced neurotoxicity: lackings, facts and future prospective 148
The "digital biopsy" in non-small cell lung cancer (NSCLC): a pilot study to predict the PD-L1 status from radiomics features of [18F]FDG PET/CT 145
MR309/E-52862, a first-in-class sigma-1 receptor antagonist, in oxaliplatin-induced peripheral neuropathy. An exploratory Phase II clinical trial 143
Efficacy of a Novel Sigma-1 Receptor Antagonist for Oxaliplatin-Induced Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Clinical Trial 141
Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: Results from a prospective multicenter study 135
Long-term course of oxaliplatin-induced polyneuropathy: a prospective two-year follow-up study 134
Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients 133
Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin 133
RNA-Based Assay for Next-Generation Sequencing of Clinically Relevant Gene Fusions in Non-Small Cell Lung Cancer 130
Vanishing bile duct syndrome following pembrolizumab infusion: case report and review of the literature 129
Dorsal sural nerve conduction study in the assessment of oxaliplatin induced peripheral neuropathy 127
The significance of dorsal sural nerve recordings in early detecting oxaliplatin-induced peripheral neuropathy. 124
Incidence, characteristics, and associations of oxaliplatin-induced peripheral neuropathy in colorectal cancer patients: Results of a prospective, multicenter, international study. 124
Peritoneal carcinomatosis in non-small-cell lung cancer: retrospective multicentric analysis and literature review 118
Metabolic parameters as biomarkers of response to immunotherapy and prognosis in non-small cell lung cancer (Nsclc): A real world experience 117
When progressive dysphagia could be related to an “old friend” – a case report 114
Major issue in chemotherapy-induced peripheral neuropathy (cipn): lack of standardized measurement scales. ciperinoms study: validity and reliability in cipn assessment 109
Clinical pattern and associations of oxaliplatin acute neurotoxicity: A prospective study in 170 patients with colorectal cancer 104
RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients 104
The Association between Vitamin D and Gut Microbiota: A Systematic Review of Human Studies 104
Thymus neuroendocrine tumors with CTNNB1 gene mutations, disarrayed ß-catenin expression, and dual intra-tumor Ki-67 labeling index compartmentalization challenge the concept of secondary high-grade neuroendocrine tumor: a paradigm shift 94
Isotretinoin plus clindamycin seem highly effective against severe erlotinib-induced skin rash in advanced non-small cell lung cancer 94
Novel cytotoxic chemotherapies in small cell lung carcinoma 90
Vitamin D supplementation and cancer mortality: Narrative review of observational studies and clinical trials 89
Disseminated intravascular coagulation in advanced lung adenocarcinoma during first-line pembrolizumab 82
High Prevalence and Early Occurrence of Skeletal Complications in EGFR Mutated NSCLC Patients With Bone Metastases 82
ALK determination: Liquid and tissue biopsy. Comparing techniques and effectiveness of alectinib in a controversial clinical case [Determinazione di ALK: Tra biopsia liquida e tissutale. Tecniche a confronto ed efficacia di alectinib in un caso clinico controverso] 80
Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients Aged ≥ 75 Years With Non–small-cell Lung Cancer (NSCLC): An Italian, Multicenter, Retrospective Study 75
Efficacy and Safety of the All-Oral Schedule of Metronomic Vinorelbine and Capecitabine in Locally Advanced or Metastatic Breast Cancer Patients: The Phase I-II VICTOR-1 Study 70
Phase I study of escalating doses of oxaliplatin in combination with fixed dose gemcitabine in patients with non-small cell lung cancer 69
Focus on nivolumab in NSCLC 66
New advances in liquid biopsy technologies for anaplastic lymphoma kinase (Alk)—positive cancer 66
Oxaliplatin doublets in non-small cell lung cancer: A literature review 65
FHIT and p53 status and response to platinum-based treatment in advanced non-small cell lung cancer 61
Trabectedin in Malignant Pleural Mesothelioma: Results From the Multicentre, Single Arm, Phase II ATREUS Study 61
Randomized phase II three-arm trial with three platinum-based doublets in metastatic non-small-cell lung cancer. An Italian Trials in Medical Oncology study 55
A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin 55
Efficacy and safety of vinorelbine-capecitabine oral metronomic combinaton in elderly metastatc breast cancer patents: VICTOR-1 study 52
Isolated cardiac metastasis from squamous cell esophageal cancer 52
Is irinotecan plus docetaxel useful as second-line therapy in advanced non-small cell lung cancer? 52
Clinical treatment of cholangiocarcinoma: an updated comprehensive review 51
Preclinical and clinical evaluation of four gemcitabine plus carboplatin schedules as front-line treatment for stage IV non-small-cell lung cancer 50
Epidermal growth factor receptor exon 20 insertion variants in non-small cell lung cancer patients 50
Vitamin D and SARS-CoV2 infection, severity and mortality: A systematic review and meta-analysis 47
Challenges in ALK inhibition of ALK-positive non-small-cell lung cancer: From ALK positivity detection to treatment strategies after relapse 47
Novel ALK mutations in EML4::ALK+ NSCLC resistant to TKIs identified by liquid biopsy 46
Targeted therapies and immunotherapy in non-small-cell lung cancer 46
What are the options for non-small-cell lung cancer patients post second-line therapy? 46
Gemcitabine-induced thrombocytosis as a potential predictive factor in non-small cell lung cancer: Analysis of 318 patients 45
Single-agent chemotherapy with vinorelbine for pretreated or metastatic squamous cell carcinoma of the esophagus 43
Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer 43
Diagnostic and prognostic biomarkers in oligometastatic non-small cell lung cancer: A literature review 42
Overall and disease-free survival greater than 12 years in metastatic non-small cell lung cancer after linear accelerator-based stereotactic radiosurgery for solitary brain metastasis 39
Aplastic anemia in a patient with advanced lung adenocarcinoma during first line osimertinib: A case report and literature review 38
Treatment patterns, clinical outcomes and healthcare costs of advanced non-small cell lung cancer: A real-world evaluation in Italy 31
An Overview of PARP Resistance in Ovarian Cancer from a Molecular and Clinical Perspective 29
Harnessing DLL3 inhibition: From old promises to new therapeutic horizons 28
Project R. Evolution for improving clinical research in Italy: challenges and strategies 27
Comment on: "is there a role for Vitamin D in human reproduction?" 25
Immune-Checkpoint-Inhibitor-Related Lung Toxicity: A Multicentre Real-Life Retrospective Portrait from Six Italian Centres 24
Sneaky Diagnosis of Pleural Malignant Mesothelioma in Thoracic Surgery: All That Glitters Is Not Gold 23
Interpretation of lung cancer study outcomes 23
Final results of DIADEM, a phase II study to investigate the efficacy and safety of durvalumab in advanced pretreated malignant pleural mesothelioma 23
Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer 20
RNA-based next-generation sequencing in non-small-cell lung cancer in a routine setting: an experience from an Italian referral center 20
Metastatic melanoma 18
Raltitrexed plus oxaliplatin in the treatment of metastatic colorectal cancer 17
Informal caregiving burden in advanced non-small cell lung cancer: the HABIT study 17
Integrated therapeutic strategies for anaplastic thyroid carcinoma 17
Pulmonary carcinoid tumours: indolent but not benign 16
Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials 16
Efficacy of treatment with irinotecan and oxaliplatin combination in FU-resistant metastatic colorectal cancer patients 16
Elapsed time for an unresolved adverse event: systemic anticancer therapy-induced neurotoxicity calls for action 15
Economic burden of patients affected by non-small cell lung cancer (NSCLC): the LIFE study 15
Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: Implications for clinical practice and open issues 15
Maintenance therapy in NSCLC: why? To whom? Which agent? 15
A new race against lung cancer 15
Targeted Therapies in Early Stage NSCLC: Hype or Hope? 15
New pan-ALK inhibitor-resistant EML4::ALK mutations detected by liquid biopsy in lung cancer patients 15
First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status 14
Totale 8.808
Salva come PNG Salva come JPEG
Categoria #
all - tutte 36.967
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 36.967
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019206 0 0 0 0 0 0 0 0 0 0 96 110
2019/20201.588 120 79 91 88 102 155 196 264 214 118 128 33
2020/20211.499 76 62 151 133 87 94 152 178 142 155 126 143
2021/20221.108 102 144 159 114 64 77 50 42 55 58 82 161
2022/20231.743 211 504 138 184 112 244 24 117 113 39 43 14
2023/20242.212 45 44 45 64 588 530 444 77 309 57 9 0
Totale 9.547